Introducing the Descriptive Framework for Assessing Epidemiological Cross-National Transferability: Application to Extrapolating Pediatric Life-Limiting Condition Prevalence Between Two European Countries
Restricted accessResearch articleFirst published online January, 2026
Introducing the Descriptive Framework for Assessing Epidemiological Cross-National Transferability: Application to Extrapolating Pediatric Life-Limiting Condition Prevalence Between Two European Countries
The transfer of epidemiological parameters, such as prevalence, between nations with limited data is a common but unstructured process. Determining how pediatric life-limiting condition (LLC) prevalence rates from one country can be applied to another country is unclear.
Objectives:
This study introduces the Descriptive Framework for Assessing Epidemiological Cross-National Transferability (FACT), a five-step approach to systematically validate and execute the transfer of epidemiological prevalence estimates.
Design:
Using the established epidemiological work by Fraser et al., the framework was applied to determine LLC prevalences in Germany (the use case).
Measurements:
Official population statistics from England and Germany were adjusted for gender and age. Results revealed that many comparative indicators were similar, deviating <2.5/5 percentage (points), supporting the transfer of English pediatric LLC prevalences to Germany.
Results:
The transfer resulted in an estimated number of 103,566 (65.30 per 10,000) German children and adolescents affected by life-shortening diseases in 2022, with projections between 107,934 and 138,817 by 2030.
Conclusions:
FACT demonstrates significant utility in transferring prevalence figures and is likely applicable to other epidemiological measures, such as incidence.
BeniniF, PapadatouD, BernadáM, et al.International standards for pediatric palliative care: From IMPaCCT to GO-PPaCS. J Pain Symptom Manage, 2022; 63(5):e529–e543.
2.
Association for Children with Life-Threatening or Terminal Conditions and Their Families; Royal College of Paediatrics and Child Health. A guide to the development of Children’s Palliative Care Services. Royal College of Paediatrics & Child Health; 1997.
3.
BjurKA, WiCI, RyuE, et al.Epidemiology of Children With Multiple Complex Chronic Conditions in a Mixed Urban-Rural US Community. Hosp Pediatr, 2019; 9(4):281–290.
4.
SidenH, SteeleR. Charting the Territory: Children and families living with progressive life-threatening conditions. Paediatr Child Health, 2015; 20(3):139–144.
5.
CarvalhoKM, de CarvalhoM, GrandoRL, et al.Children with complex chronic conditions: An evaluation from the standpoint of academic publications. Int J Contemp Pediatr, 2021; 8(3):594–601.
6.
CohenE, KuoDZ, AgrawalR, et al.Children with medical complexity: An emerging population for clinical and research initiatives. Pediatrics, 2011; 127(3):529–538.
7.
WardMM. Estimating disease prevalence and incidence using administrative data: Some assembly required. J Rheumatol, 2013; 40(8):1241–1243.
8.
Nguengang WakapS, LambertDM, OlryA, et al.Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database. Eur J Hum Genet, 2020; 28(2):165–173.
9.
NicodE, LloydAJ, MorelT, et al.Improving interpretation of evidence relating to quality of life in health technology assessments of rare disease treatments. Patient, 2023; 16(1):7–17.
10.
ShourickJ, WackM, JannotA-S. Assessing rare diseases prevalence using literature quantification. Orphanet J Rare Dis, 2021; 16(1):139.
11.
MaikeS, WandreyM, HeringR, et al.Prävalenz seltener Erkrankungen in der ambulanten Versorgung in Deutschland im Zeitraum. Versorgungsatlas; 2008, bis 2011.
12.
FraserLK, MillerM, HainR, et al.Rising national prevalence of life-limiting conditions in children in England. Pediatrics, 2012; 129(4):e923–e929.
13.
FraserLK, Gibson-SmithD, JarvisS, et al.Estimating the current and future prevalence of life-limiting conditions in children in England. Palliat Med, 2021; 35(9):1641–1651.
14.
BergsträsserE. Pädiatrische Palliative Care: Was ist bei Kindern anders als bei Erwachsenen. Ther Umsch, 2018; 75(2):101–104.
15.
BubbM, CalahorranoL, RebaudoM. Mikrodaten zur Evaluation der palliativen Versorgung von Kindern und Jugendlichen. In Studie im Auftrag des Bundesministeriums für Familien, Senioren, Frauen und Jugend. Sankt Augustin; 2020.
16.
St SauverJL, GrossardtBR, LeibsonCL, et al.Generalizability of epidemiological findings and public health decisions: An illustration from the Rochester Epidemiology Project. Mayo Clin. Proc, 2012; 87(2):151–160.
17.
NixonJ, RiceS, DrummondM, et al.Guidelines for completing the EURONHEED transferability information checklists. Eur J Health Econ, 2009; 10(2):157–165.
18.
LeskoCR, FoxMP, EdwardsJK. A Framework for Descriptive Epidemiology. Am J Epidemiol, 2022; 191(12):2063–2070.
19.
KukullWA, GanguliM. Generalizability: The trees, the forest, and the low-hanging fruit. Neurology, 2012; 78(23):1886–1891.
20.
BenjafieldAV, AyasNT, EastwoodPR, et al.Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis. Lancet Respir Med, 2019; 7(8):687–698.
21.
ResnikoffS, PascoliniD, Etya’aleD, et al.Global data on visual impairment in the year 2002. Bull World Health Organ, 2004; 82(11):844–851.
22.
OgleGD, JamesS, DabeleaD, et al.Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 10th edition. Diabetes Res. Clin. Pract, 2022; 183:109083. Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 10th edition.
23.
PickvanceCG. Four varieties of comparative analysis. Journal of Housing and the Built Environment, 2001; 16(1):7–28.
24.
LandmanT. Issues and methods in comparative politics: an introduction. Routledge; 2002.
25.
MurrayCJ. Towards good practice for health statistics: Lessons from the Millennium Development Goal health indicators. Lancet, 2007; 369(9564):862–873.
26.
ElliottH. European Union health information infrastructure and policy. In European Union Public Health Policy. Routledge; 2013, pp. 36–50.
27.
BozC, SurH, SöyükS. The similarities and differences analysis of OECD countries in terms of health system indicators. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, 2016.
Institute for Quality Assurance and Transparency in the Healthcare Sector (IQTIG). Federal Evaluation - Perinatal medicine: Obstetrics 2021 Perinatalmedizin: Geburtshilfe. Bundesauswertung; 2022.
38.
Office for National Statistics. Birth characteristics 2022. 2022.
TatemKS, RomoML, McVeighKH, et al.Comparing Prevalence Estimates From Population-Based Surveys to Inform Surveillance Using Electronic Health Records. Prev Chronic Dis, 2017; 14:E44.
65.
Montserrat MolinerA, WaligóraJ. The European Union Policy in the Field of Rare Diseases. Public Health Genomics, 2013; 16(6):268–277.
66.
ShangZ. Use of Delphi in health sciences research: A narrative review. Medicine (Baltimore) ). 2023; 102(7):e32829.
CholaL, FrønsdalK, HeupinkLF, et al.Considerations for transferability of health technology assessments: A scoping review of tools, methods, and practices. Int. J. Technol. Assess. Health Care, 2022; 38(1):e78.
72.
GroftSC, de la PazMP. Rare diseases—avoiding misperceptions and establishing realities: the need for reliable epidemiological data. In:. Rare Diseases Epidemiology. (Posada de la PazM, GroftSC., eds.) Dordrecht: Springer Netherlands; 2010, pp. 3–14.
73.
LomasT. A provisional global comparison framework: One hundred psychologically salient ways of conceptualizing and evaluating the world. Intnl J Wellbeing, 2023; 13(4):1–25.
74.
JaksaA, ArenaPJ, ChanKKW, et al.Transferability of real-world data across borders for regulatory and health technology assessment decision-making. Front Med (Lausanne), 2022; 9:1073678.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
